Circulating folate and folic acid concentrations: Associations with colorectal cancer recurrence and survival

Anne J.M.R. Geijsen, Arve Ulvik, Biljana Gigic, Dieuwertje E. Kok, Fränzel J.B. Van Duijnhoven, Andreana N. Holowatyj, Stefanie Brezina, Eline H. Van Roekel, Andreas Baierl, Michael M. Bergmann, Jürgen Böhm, Martijn J.L. Bours, Hermann Brenner, Stéphanie O. Breukink, Mary P. Bronner, Jenny Chang-Claude, Johannes H.W. De Wilt, William M. Grady, Thomas Grünberger, Tanja GumpenbergerEsther Herpel, Michael Hoffmeister, Lyen C. Huang, Jolanta D. Jedrzkiewicz, Eric T.P. Keulen, Rama Kiblawi, Torsten Kölsch, Janna L. Koole, Katharina Kosma, Ewout A. Kouwenhoven, Flip M. Kruyt, Gry Kvalheim, Christopher I. Li, Tengda Lin, Jennifer Ose, T. Bartley Pickron, Courtney L. Scaife, Peter Schirmacher, Martin A. Schneider, Petra Schrotz-King, Marie C. Singer, Eric R. Swanson, Peter Van Duijvendijk, Henk K. Van Halteren, Moniek Van Zutphen, Kathy Vickers, F. Jeroen Vogelaar, Evertine Wesselink, Nina Habermann, Alexis B. Ulrich, Per M. Ueland, Matty P. Weijenberg, Andrea Gsur, Cornelia M. Ulrich, Ellen Kampman

Research output: Contribution to JournalReview articleAcademicpeer-review

Abstract

Background: Folates, including folic acid, may play a dual role in colorectal cancer development. Folate is suggested to be protective in early carcinogenesis but could accelerate growth of premalignant lesions or micrometastases. Whether circulating concentrations of folate and folic acid, measured around time of diagnosis, are associated with recurrence and survival in colorectal cancer patients is largely unknown. Methods: Circulating concentrations of folate, folic acid, and folate catabolites p-aminobenzoylglutamate and p-acetamidobenzoylglutamate were measured by liquid chromatography-tandem mass spectrometry at diagnosis in 2024 stage I-III colorectal cancer patients from European and US patient cohort studies. Multivariable-adjusted Cox proportional hazard models were used to assess associations between folate, folic acid, and folate catabolites concentrations with recurrence, overall survival, and disease-free survival. Results: No statistically significant associations were observed between folate, p-aminobenzoylglutamate, and p-acetamidobenzoylglutamate concentrations and recurrence, overall survival, and disease-free survival, with hazard ratios ranging from 0.92 to 1.16. The detection of folic acid in the circulation (yes or no) was not associated with any outcome. However, among patients with detectable folic acid concentrations (n=296), a higher risk of recurrence was observed for each twofold increase in folic acid (hazard ratio = 1.31, 95% confidence interval = 1.02 to 1.58). No statistically significant associations were found between folic acid concentrations and overall and disease-free survival. Conclusions: Circulating folate and folate catabolite concentrations at colorectal cancer diagnosis were not associated with recurrence and survival. However, caution is warranted for high blood concentrations of folic acid because they may increase the risk of colorectal cancer recurrence.
Original languageEnglish
Article numberpkaa051
JournalJNCI Cancer Spectrum
Volume4
Issue number5
DOIs
Publication statusPublished - 2021
Externally publishedYes

Funding

This work was supported by Wereld Kanker Onderzoek Fonds (WKOF) and World Cancer Research Fund International (WCRF International); the World Cancer Research Fund International Regular Grant Programme (WKOF/WCRF, the Netherlands, project no. 2014/1179); Alpe d’Huzes/Dutch Cancer Society (KWF Kankerbestrijding, the Netherlands, project no. UM 2010-4867, UM 2012-5653, UW 2013-5927, UW 2015-7946); ERA-NET on Translational Cancer Research (TRANSCAN/Dutch Cancer Society, the Netherlands, project no. UW 2013-6397, UM 2014-6877); the Netherlands Organization for Health Research and Development (ZonMw, the Netherlands); the Austrian Science Fund (FWF, Austria; project no. I 2104-B26); the Federal Ministry of Education and Research (BMBF, Germany; project no. 01KT1503); The Research Council of Norway (RCN, Norway; project no. 246402/H10); the National Cancer Institute (NCI, United States; project no. R01 CA189184, U01 CA206110, R01 CA207371); the Huntsman Cancer Foundation (HCI, U.S.); the National Institutes of Health (NIH, United States; grant no. P30 CA015704, P30 CA042014, U01 CA152756, R01 CA194663, and R01 CA220004) coordinated by the ERA-NET, JTC 2013 call on Translational Cancer Research (TRANSCAN). In addition, D. E. Kok is supported by a Veni grant (grant no. 016.Veni.188.082) of the Netherlands Organisation for Scientific Research. W. M. Grady is funded by the Fred Hutchinson Cancer Research Center, the Seattle Translational Tumor Research Program, and the Cottrell Family. A. N. Holowatyj was supported by the National Institutes of Health under Ruth L. Kirschstein National Research Service Award from the National Human Genome Research Institute (grant no. T32 HG008962). E. H. van Roekel was financially supported by Wereld Kanker Onderzoek Fonds (WKOF) as part of the World Cancer Research Fund International grant program (grant no. 2016/ 1620). J. L. Koole and M. J. L. Bours were financially This work was supported by Wereld Kanker Onderzoek Fonds (WKOF) and World Cancer Research Fund International (WCRF International); the World Cancer Research Fund International Regular Grant Programme (WKOF/WCRF, the Netherlands, project no. 2014/1179); Alpe d'Huzes/Dutch Cancer Society (KWF Kankerbestrijding, the Netherlands, project no. UM 2010-4867, UM 2012-5653, UW 2013-5927, UW 2015-7946); ERA-NET on Translational Cancer Research (TRANSCAN/Dutch Cancer Society, the Netherlands, project no. UW 2013-6397, UM 2014-6877); the Netherlands Organization for Health Research and Development (ZonMw, the Netherlands); the Austrian Science Fund (FWF, Austria; project no. I 2104-B26); the Federal Ministry of Education and Research (BMBF, Germany; project no. 01KT1503); The Research Council of Norway (RCN, Norway; project no. 246402/H10); the National Cancer Institute (NCI, United States; project no. R01 CA189184, U01 CA206110, R01 CA207371); the Huntsman Cancer Foundation (HCI, U.S.); the National Institutes of Health (NIH, United States; grant no. P30 CA015704, P30 CA042014, U01 CA152756, R01 CA194663, and R01 CA220004) coordinated by the ERA-NET, JTC 2013 call on Translational Cancer Research (TRANSCAN). In addition, D. E. Kok is supported by a Veni grant (grant no. 016.Veni.188.082) of the Netherlands Organisation for Scientific Research. W. M. Grady is funded by the Fred Hutchinson Cancer Research Center, the Seattle Translational Tumor Research Program, and the Cottrell Family. A. N. Holowatyj was supported by the National Institutes of Health under Ruth L. Kirschstein National Research Service Award from the National Human Genome Research Institute (grant no. T32 HG008962). E. H. van Roekel was financially supported by Wereld Kanker Onderzoek Fonds (WKOF) as part of the World Cancer Research Fund International grant program (grant no. 2016/ 1620). J. L. Koole and M. J. L. Bours were financially supported by Kankeronderzoekfonds Limburg as part of Health Foundation Limburg (grant no. 00005739). supported by Kankeronderzoekfonds Limburg as part of Health Foundation Limburg (grant no. 00005739).

FundersFunder number
ERA-NET on Translational Cancer Research
Seattle Translational Tumor Research Program
TRANSCANUM 2014-6877, UW 2013-6397
National Institutes of HealthP30 CA042014, R01 CA194663, P30 CA015704, R01 CA220004, U01 CA152756
National Human Genome Research Institute00005739, 2016/ 1620, T32 HG008962
National Cancer InstituteR01 CA189184, R01 CA207371, U01 CA206110
Huntsman Cancer Foundation
World Cancer Research Fund International
World Cancer Research Fund2014/1179
ZonMw
Bundesministerium für Bildung und Forschung01KT1503
Austrian Science Fund2104-B26
Nederlandse Organisatie voor Wetenschappelijk Onderzoek
KWF KankerbestrijdingUM 2012-5653, UM 2010-4867, UW 2013-5927, UW 2015-7946
Norges forskningsråd246402/H10
Wereld Kanker Onderzoek Fonds

    Fingerprint

    Dive into the research topics of 'Circulating folate and folic acid concentrations: Associations with colorectal cancer recurrence and survival'. Together they form a unique fingerprint.

    Cite this